Phase I/II Study of the Combination of Quizartinib (AC220) With 5-Azacytidine or Low-Dose Cytarabine for the Treatment of Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Trial Profile

Phase I/II Study of the Combination of Quizartinib (AC220) With 5-Azacytidine or Low-Dose Cytarabine for the Treatment of Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 14 Mar 2017

At a glance

  • Drugs Quizartinib (Primary) ; Azacitidine; Azacitidine; Cytarabine
  • Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 06 Dec 2016 Results of interim analysis (n=52) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
    • 09 Dec 2014 Interim results (n=26) presented at the 56th Annual Meeting and Exposition of the American Society of Hematology.
    • 07 Apr 2014 Full results, including data from the phase II cohort, are expected to be submitted to a medical conference in 2014, according to an Ambit Biosciences media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top